All In Biotech

Drug Trial Radar · NCT00744263

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease

Last checked: Nov 19, 2026Latest source record: Oct 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 84,496 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84,496

Actual

Start

Sep 2008

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 29, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

Conditions

  • Pneumonia, Pneumococcal
  • Pneumococcal Infections
  • 13-valent Pneumococcal Vaccine

Interventions

  • VACCINE: placeboBiological

    0.5 mL, single intra-muscular injection

  • VACCINE: 13-valent pneumococcal conjugate vaccineBiological

    0.5 mL, single intra-muscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)Time frame: Baseline up to occurrence of first episode of VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)

Locations

159 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Abbekerk, Netherlands

  • Pfizer Investigational Site

    Alkmaar, Netherlands

  • Pfizer Investigational Site

    Alkmaar, Netherlands

  • Pfizer Investigational Site

    Almelo, Netherlands

  • Pfizer Investigational Site

    Almere Stad, Netherlands

  • Pfizer Investigational Site

    Almere Stad, Netherlands

  • Pfizer Investigational Site

    Alphen aan den Rijn, Netherlands

  • Pfizer Investigational Site

    Amersfoort, Netherlands

  • Pfizer Investigational Site

    Amersfoort, Netherlands

  • Pfizer Investigational Site

    Amstelveen, Netherlands

  • Pfizer Investigational Site

    Amstelveen, Netherlands

  • Pfizer Investigational Site

    Amsterdam, Netherlands

  • Pfizer Investigational Site

    Amsterdam, Netherlands

  • Pfizer Investigational Site

    Amsterdam, Netherlands

  • Pfizer Investigational Site

    Amsterdam, Netherlands

  • Pfizer Investigational Site

    Amsterdam, Netherlands

  • Pfizer Investigational Site

    Amsterdam, Netherlands

  • Pfizer Investigational Site

    Amsterdam, Netherlands

  • Pfizer Investigational Site

    Apeldoorn, Netherlands

  • Pfizer Investigational Site

    Apeldoorn, Netherlands

  • Pfizer Investigational Site

    Apeldoorn, Netherlands

  • Pfizer Investigational Site

    Arnhem, Netherlands

  • Pfizer Investigational Site

    Arnhem, Netherlands

  • Pfizer Investigational Site

    Assen, Netherlands

  • Pfizer Investigational Site

    Assen, Netherlands

  • Pfizer Investigational Site

    Baarle-Nassau, Netherlands

  • Pfizer Investigational Site

    Baarn, Netherlands

  • Pfizer Investigational Site

    Bedum, Netherlands

  • Pfizer Investigational Site

    Bennebroek, Netherlands

  • Pfizer Investigational Site

    Bergen op Zoom, Netherlands

  • Pfizer Investigational Site

    Bergen op Zoom, Netherlands

  • Pfizer Investigational Site

    Berkel-Enschot, Netherlands

  • Pfizer Investigational Site

    Berkhout, Netherlands

  • Pfizer Investigational Site

    Bilthoven, Netherlands

  • Pfizer Investigational Site

    Blaricum, Netherlands

  • Pfizer Investigational Site

    Breda, Netherlands

  • Pfizer Investigational Site

    Breda, Netherlands

  • Pfizer Investigational Site

    Breda, Netherlands

  • Pfizer Investigational Site

    Brunssum, Netherlands

  • Pfizer Investigational Site

    Deventer, Netherlands

Showing 40 of 159 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.